$43.95
0.05[0.11%]
At close: May 7
$43.95
0[0.00%]
After Hours: 7:02PM EDT
Bristol-Myers Squibb
(NYSE:BMY)Latest News for Bristol-Myers Squibb Stock (NYSE:BMY)
Bristol-Myers Squibb Stock (NYSE: BMY)
Categories: All
Tuesday, May 07, 2024
Monday, May 06, 2024
- European Medicines Agency Validates Type 2 Variation Application For Bristol Myers Squibb's Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) For First-line Treatment Of Microsatellite Instability–High Or Mismatch Repair Deficient Metastatic Colorectal CancerBenzinga Newsdesk - 1 day ago
- FDA Bristol Myers Squibb's Application For Subcutaneous Nivolumab (Nivolumab And Hyaluronidase), With Prescription Drug User Fee Act Goal Date Of February 28, 2025Benzinga Newsdesk - 1 day ago
Friday, May 03, 2024
Tuesday, April 30, 2024
Monday, April 29, 2024
- How Is The Market Feeling About Bristol-Myers Squibb?Benzinga Insights - Apr 29, 2024, 11:45AM
- Bristol Myers Squibb and Repertoire Announce $1.8B Deal to Reset Immune System in Autoimmune PatientsBenzinga Newsdesk - Apr 29, 2024, 6:03AM
- Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This WeekShanthi Rexaline - Apr 29, 2024, 1:51AM
Sunday, April 28, 2024
Friday, April 26, 2024
- BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Lowers Price Target to $48Benzinga Newsdesk - Apr 26, 2024, 2:10PM
- Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst InsightsBenzinga Insights - Apr 26, 2024, 1:00PM
- Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $43Benzinga Newsdesk - Apr 26, 2024, 9:33AM
- Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial CarcinomaBenzinga Newsdesk - Apr 26, 2024, 7:04AM
- Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 PointsAvi Kapoor - Apr 26, 2024, 2:59AM
Thursday, April 25, 2024
- Bristol-Myers Q1 Loss Narrower Than Expected, Sales BeatZacks - Apr 25, 2024, 10:16PM
- Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 ResultsAvi Kapoor - Apr 25, 2024, 2:32PM
- Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - Apr 25, 2024, 1:57PM
- Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion AcquisitionsVandana Singh - Apr 25, 2024, 12:23PM
- Bristol-Myers Squibb shares are trading lower following Q1 earnings.Benzinga Newsdesk - Apr 25, 2024, 9:02AM
- Bristol Myers Squibb Revises 2024 Adjusted EPS Guidance From $7.10-$7.40 To $0.40-$0.70 Versus Consensus Of $0.66, Reflecting The Impact Of Recent TransactionsBenzinga Newsdesk - Apr 25, 2024, 7:12AM
- Bristol Myers Squibb Says It Is Executing Strategic Productivity Initiative To Deliver ~$1.5B In Cost Savings, The Majority Of Which Will Be Reinvested To Fund Innovation And Drive GrowthBenzinga Newsdesk - Apr 25, 2024, 7:08AM
- Bristol-Myers Squibb Q1 2024 Adj EPS $(4.40) Beats $(4.44) Estimate, Sales $11.865B Beat $11.458B EstimateBenzinga Newsdesk - Apr 25, 2024, 7:07AM
- US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says AnalystShanthi Rexaline - Apr 25, 2024, 6:17AM
Wednesday, April 24, 2024
Tuesday, April 23, 2024
Sunday, April 21, 2024
Friday, April 19, 2024
Thursday, April 18, 2024
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
- Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain MutationVandana Singh - Apr 8, 2024, 2:00PM
- Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal CancerBenzinga Newsdesk - Apr 8, 2024, 11:31AM
- Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other AntipsychoticsVandana Singh - Apr 8, 2024, 10:31AM
- Reported Saturday, Bristol Myers Squibb Presented New Interim Long-Term Efficacy Data From The EMERGENT-4 Trial Evaluating Karxt In Schizophrenia At The 2024 Annual Congress Of The SIRSBenzinga Newsdesk - Apr 8, 2024, 3:11AM
Friday, April 05, 2024
- FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary CancerVandana Singh - Apr 5, 2024, 1:37PM
- At An Estimated Median Duration Of Follow-Up Of 15.9 Months At The Primary PFS Analysis, Abecma More Than Tripled The Primary Endpoint Of PFS Compared With Standard RegimensBenzinga Newsdesk - Apr 5, 2024, 9:09AM
- U.S. FDA Approves Bristol Myers Squibb And 2seventy bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 KarMMa-3 trial, With A 51% Reduction In Risk Of Disease Progression Or Death And A Well-Established Safety ProfileBenzinga Newsdesk - Apr 5, 2024, 9:07AM
Thursday, April 04, 2024
Wednesday, April 03, 2024
- Standard BioTools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb For Use Of The SomaScan Platform For Translational Medicine Research Through 2026Benzinga Newsdesk - Apr 3, 2024, 4:02PM
- Reported Earlier, European Commission Expands Approval Of Bristol Myers Squibb's Reblozyl® To Include First-Line Treatment Of Transfusion-Dependent Anemia In Adults With Lower-Risk Myelodysplastic SyndromesBenzinga Newsdesk - Apr 3, 2024, 2:31AM